Study of nimotuzumab plus adebrelimab with chemo for head and neck cancer patients who cannot take cisplatin
Part of Cancer clinical trials.
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have head and neck squamous cell cancer that has come back or spread, and cannot be cured with local treatments like surgery or radiation.
- You have not had any previous chemotherapy, targeted therapy, or immunotherapy for this cancer after it came back or spread.
- You cannot take cisplatin because you are over 70, have a poor performance status (ECOG 2), poor kidney function, hearing loss, heart problems, or you choose not to take it.
- You have at least one tumor that can be measured on scans.
- You are willing to provide a tumor sample for testing (or have one already tested) and your blood counts, kidney, and liver function are adequate.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after the last dose.
- You have no other active cancers, severe infections, autoimmune diseases, or brain metastases that are not stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.